Advances in microbicide vaginal rings
- PMID: 21109066
- DOI: 10.1016/j.antiviral.2010.09.003
Advances in microbicide vaginal rings
Abstract
Vaginal ring devices capable of providing sustained/controlled release of incorporated actives are already marketed for steroidal contraception and estrogen replacement therapy. In recent years, there has been considerable interest in developing similar ring devices for the administration of microbicidal compounds to prevent vaginal HIV transmission. Intended to be worn continuously, such coitally independent microbicide rings are being developed to maintain effective vaginal microbicide concentrations over many weeks or months, thereby overcoming issues around timing of product application, user compliance and acceptability associated with more conventional semi-solid formulations. In this article, an overview of vaginal ring technologies is presented, followed by a review of recent advances and issues pertaining to their application for the delivery of HIV microbicides. This article forms part of a special supplement on presentations covering intravaginal rings, based on the symposium "Trends in Microbicide Formulations", held on 25 and 26 January 2010, Arlington, VA.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.Antiviral Res. 2010 Dec;88 Suppl 1:S55-66. doi: 10.1016/j.antiviral.2010.09.006. Antiviral Res. 2010. PMID: 21109069
-
Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.Antiviral Res. 2010 Dec;88 Suppl 1:S19-29. doi: 10.1016/j.antiviral.2010.09.010. Antiviral Res. 2010. PMID: 21109064 Review.
-
Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.Antiviral Res. 2010 Dec;88 Suppl 1:S47-54. doi: 10.1016/j.antiviral.2010.09.005. Antiviral Res. 2010. PMID: 21109068 Review.
-
Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.Antiviral Res. 2010 Dec;88 Suppl 1:S10-8. doi: 10.1016/j.antiviral.2010.09.018. Antiviral Res. 2010. PMID: 21109063 Review.
-
Clinical evaluation of microbicide formulations.Antiviral Res. 2010 Dec;88 Suppl 1(Suppl 1):S40-6. doi: 10.1016/j.antiviral.2010.09.008. Antiviral Res. 2010. PMID: 21109067 Free PMC article. Review.
Cited by
-
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.J Antimicrob Chemother. 2012 Jul;67(7):1730-8. doi: 10.1093/jac/dks097. Epub 2012 Mar 30. J Antimicrob Chemother. 2012. PMID: 22467632 Free PMC article.
-
Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.Antimicrob Agents Chemother. 2012 Nov;56(11):5952-60. doi: 10.1128/AAC.01198-12. Epub 2012 Sep 10. Antimicrob Agents Chemother. 2012. PMID: 22964245 Free PMC article.
-
Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females.Int J Womens Health. 2012;4:341-50. doi: 10.2147/IJWH.S27601. Epub 2012 Jul 19. Int J Womens Health. 2012. PMID: 22927765 Free PMC article.
-
Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.Cell Mol Life Sci. 2015 Feb;72(3):469-503. doi: 10.1007/s00018-014-1756-3. Epub 2014 Oct 17. Cell Mol Life Sci. 2015. PMID: 25323132 Free PMC article. Review.
-
Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model.Antimicrob Agents Chemother. 2013 Aug;57(8):3994-7. doi: 10.1128/AAC.00547-13. Epub 2013 Jun 10. Antimicrob Agents Chemother. 2013. PMID: 23752507 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical